BNT-325 by BioNTech for Malignant Mesothelioma: Likelihood of Approval

BNT-325 is under clinical development by BioNTech and currently in Phase II for Malignant Mesothelioma.

Early cancer vaccine data breathe new life into the field, but many questions remain: #AACR24

SAN DIEGO — Scientists have long dreamed of creating vaccine-like treatments that could teach the immune system to target tumors. After decades of false starts, that

April 11, 2024

Survey sabotage: careless and inattentive participants misrepresent COVID-19 cleaning habits

Surveys are the most common approaches for collecting data in public health.

July 7, 2023

NICE recommends Lilly’s tirzepatide for type 2 diabetes treatment

Tirzepatide is intended for use in adult patients with inadequately controlled type 2 diabetes. Credit: joshimerbin / Shutterstock.com. The UK National Institute for Health and

September 8, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.